DDP – Drug-Development-Project
Identification of new active compounds with completely novel modes of action is one of the biggest challenges for the further improvement of human health on a global scale. The Leibniz-HKI with its main research topics microbial natural product research and infection biology of human pathogenic fungi addresses this challenge. The required critical mass and competitiveness has been achieved by strategically developing the institute with regard to both personnel and infrastructure.
The Drug-Development-Package combines the most potent currently available technologies which allow a systematic identification and optimization of new inhibitor classes with high target specificity. In conjunction with already established methods for biological testing, biotechnological production, expertise in medicinal chemistry, ADME characterisation and animal experiments, a complete process chain can be created that provides a unique advantage.
This project is financed by InfectControl 2020.